fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ropinirole

All products: not a benefit

ReQuip · DIN 02232568 · 2 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.Discontinued March 2, 2018 · checked November 17, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-03-02 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
ReQuip · DIN 02232568 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-04-17 Health Canada: Cancelled post market since 2018-03-02 · brand REQUIP · ATC N04BC04 ROPINIROLE · form Tablet · route Oral · ingredients ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

ReQuip: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02232568)

Source record
DIN 02232568: ReQuip Raw flags: notABenefit=Y, sec3=Y Item: 920000291; group id 956; item number 2271; lccId None; manufacturer id GSK Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02232568 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52044
Interchangeable products
Ran-Ropinirole · DIN 02314061 · $0.6338 Teva-Ropinirole · DIN 02316862 · $0.6338
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since March 2, 2018 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N04B, N04BC): coverage varies; not interchangeable

  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Amantadine (Symmetrel): general benefit, not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, limited Use, not a benefit
  • Selegiline (Eldepryl): general benefit, not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults: SPC-ROPINIROLE (Ropinirole Tablets) is indicated in the treatment of the signs and symptoms of idiopathic Parkinson's disease. SPC-ROPINIROLE can be used both as early therapy without concomitant levodopa and as an adjunct to levodopa. Geriatrics (> 65 years of age): Oral clearance of SPC-ROPINIROLE is reduced in patients older than 65 years of age, however the dosing of ropinirole for elderly patients can be titrated in the normal manner. (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Paediatrics (≤ 18 years of age): The safety and efficacy of Ropinirole Tablets have not been established in children under 18 years of age, therefore SPC-ROPINIROLE is not recommended in this patient population. https://pdf.hres.ca/dpd_pm/00081006.PDF PM date: JUN 26, 2025 Source product: SPC-ROPINIROLE; DIN 02314037; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For ReQuip: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026